Cancer– tag –
-
Oncology FDA Approval
Oncology Drug Approval News Flash: FDA Approves Selumetinib (KOSELUGO) for Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, 2025, the U.S. Food and Drug Administration (FDA) approved selumetinib (KOSELUGO, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously appro... -
Oncology FDA Approval
Oncology Drug Approval News Flash: FDA Approves Epcoritamab-bysp (Epkinly) with R² for Relapsed or Refractory Follicular Lymphoma
On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved epcoritamab-bysp (Epkinly, Genmab / AbbVie) in combination with lenalidomide and rituximab (R²) for adults with relapsed or refractory follicular lymphoma (FL). T... -
Beginner-friendly
Cancer Treatment: Introductory–to–Basic Series – Part 1
Understanding the Overall Picture of Cancer Treatment and Why Some Cancers Are “Easier” or “Harder” to Cure “Can cancer really be cured?” “If it comes back, does that mean it is over?” These are among the most common and most painful que... -
Oncology Drug
New Series|Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 6 Final: BRD4 and CDK Crosstalk — The Future of Super-Enhancer Targeting)
From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. In this final installment, we turn to BRD4, a pivotal co-regulator that interacts closely with CDKs and controls super-enhancer–driv... -
Oncology FDA Approval
Oncology Drug Approval News Flash: FDA Approves Poherdy (pertuzumab-dpzb) as the First Interchangeable Biosimilar to Perjeta
On November 13, 2025, the U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics) as the first interchangeable biosimilar to Perjeta (pertuzumab, Genentech). This marks a historic step in ex... -
Oncology Drug
New Series|Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 5: CDK11 — Pause-Checkpoint and Emerging Therapeutic Potential)
In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. Here in Part 5, we focus on CDK11, a kinase that has recently gained attention for its role as a pause-checkpoint regulator in transcription, preceding... -
Oncology Drug
New Series|Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 4: CDK12 & CDK13 — DNA Repair and Synthetic Lethality Strategies)
In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of genome stability and represent key players in... -
Oncology Drug
New Series|Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 3: CDK9 — The Bottleneck of Transcription Elongation and Clinical Development)
In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. Here in Part 3, we focus on CDK9, the central kinase controlling the transition from paused RNA polymerase II (Pol II) to productive elongation. Among transcripti... -
Oncology Drug
New Series|Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 2: CDK7 & CDK8 — Gatekeepers of Transcription Initiation and Emerging Therapeutics)
In Part 1, we reviewed the fundamentals of transcription and the CDK family. In this article, we focus on CDK7 and CDK8, two kinases that act at the transcriptional “starting line.” While both regulate initiation, their roles and drug di... -
Oncology Drug
New Series|Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 0: Introduction and Overview)
This series focuses on the transcriptional machinery as an emerging target for cancer therapy, highlighting CDK (Cyclin-Dependent Kinases) families involved in transcription and BRD4. While CDK4/6 inhibitors have already transformed onco... -
Oncology FDA Approval
Oncology Drug Approval News Flash: FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma
On November 6, 2025, the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj, Janssen Biotech, Inc.) for the treatment of adults with high-risk smoldering multiple myeloma (SMM). This mark... -
Oncology Drug
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 6 (Finale)
What’s Next — GDF15 Blockade and the Era of Precise Phenotypes Our finale focuses on near-future therapies and trial design. Beyond “weight,” we target phenotype × mechanism and build evidence that actually changes care. 3 takeaways Dire... -
Oncology Drug
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 5
What Works Today — Nutrition, Exercise, Anti-inflammation, and Current Drugs Part 5 is a how-to guide. We align home and clinic workflows and run nutrition, resistance exercise, inflammation/symptom control as a package. Medications are ... -
Oncology Drug
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 4
What Breaks in CAC? — Human Evidence on Appetite, Metabolism, Fat & Muscle In Part 4 we look behind the scenes using human data: central appetite circuits, systemic metabolism, adipose tissue, and skeletal muscle. We map these mechan... -
Oncology Drug
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 3
Making CAC Visible — Phenotyping with CT, Function, and PROs Part 3 is a practical guide to phenotyping in clinic. Combine CT body composition, simple functional tests, and patient-reported outcomes (PROs) to sort patients into actionabl... -
Oncology Drug
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 1
What Is CAC? — The Disease You Can’t See by Weight Alone This is a “super-basic” primer for patients, families, and general readers. We minimize jargon and focus on signs you can notice at home and what to bring to clinic visits. Why wei... -
Oncology Drug
New Horizons in Biliary Tract Cancer: Insights from Cancer Discovery on Molecular Subtypes and Therapeutic Targets
Biliary tract cancer (BTC), encompassing intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder cancer, remains a highly lethal malignancy with limited treatment options. In 2025, Cancer Discovery published a landmark st... -
Oncology Drug
ecDNA in Glioblastoma: Spatial Heterogeneity and EGFRvIII Evolution (Part 2)
This Part focuses on how extrachromosomal DNA (ecDNA) shapes spatial heterogeneity and evolution in glioblastoma (GBM). We outline the extreme copy-number gains of drivers (EGFR/PDGFRA/CDK4) on ecDNA, region-to-region response gaps, and ... -
Oncology Drug
ecDNA in Cancer: Mechanisms of Diversity and Resistance (Part 1)
Extrachromosomal DNA (ecDNA) reshapes oncogene dosage, transcription, phenotypes, and spatial organization, thereby accelerating intratumor heterogeneity and therapy resistance. In Part 1, we briefly introduce non-GBM evidence up front a... -
Oncology Drug
KRAS Special Series Part 8 (Final): The Next Decade — From Cancer Control to Regeneration and Longevity
For over four decades, KRAS symbolized the “undruggable.” By the mid-2020s, it became the flagship of precision oncology. This final chapter summarizes that evolution—from structural biology to AI-driven therapeutics—and looks ahead to h...